The potential for tolerance in pediatric renal transplantation

Current Opinion in Organ Transplantation

Volumn 13, Issue 5, 2008, Pages 489-494

  Traum, Avram Z ^a   Ko, Dicken S C ^b   Kawai, Tatsuo ^b  

^a Pediatric Nephrology Unit   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Adolescent; Kidney transplantation; Pediatric; Tolerance

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BELATACEPT; CORTICOSTEROID; CYCLOSPORIN; LYMPHOCYTE ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; ADOLESCENCE; BONE MARROW TRANSPLANTATION; CHIMERA; CLINICAL TRIAL; DRUG WITHDRAWAL; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LONG TERM CARE; LOW DRUG DOSE; LYMPH NODE IRRADIATION; LYMPHOCYTE DEPLETION; LYMPHOPROLIFERATIVE DISEASE; MICROCHIMERISM; NONHUMAN; OPPORTUNISTIC INFECTION; PEDIATRIC SURGERY; RADIATION DOSE; REVIEW; ADOLESCENT; CHILD PSYCHOLOGY; COST OF ILLNESS; HISTOCOMPATIBILITY; IMMUNOLOGY; METHODOLOGY; PATIENT COMPLIANCE; PSYCHOLOGICAL ASPECT; RADIOTHERAPY;

ADOLESCENT; ADOLESCENT PSYCHOLOGY; BONE MARROW TRANSPLANTATION; COST OF ILLNESS; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LYMPHATIC IRRADIATION; LYMPHOCYTE DEPLETION; MEDICATION ADHERENCE; TRANSPLANTATION CHIMERA;

EID: 60849110857     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e328310b0cd     Document Type: Review

References (61)

1. Billingham RE, Brent L, Medawar PB. Actively acquired tolerance of foreign cells. Nature 1953; 172:603-606.
2. Merrill JP, Murray JE, Harrison JH, Guild WR. Successful homotransplantation of the human kidney between identical twins. JAMA 1956; 160:277-282.
3. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004; 4:378-383.
4. Hanto DW, Frizzera G, Gajl-Peczalska KJ, et al. Epstein-Barr virus-induced B-cell lymphoma after renal transplantation: acyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation. N Engl J Med 1982; 306: 913-918.
5. Leech SH, Kumar P. Epstein-Barr virus-induced B-cell lymphoma after renal transplantation. N Engl J Med 1982; 307:896-897.
6. Green M, Webber S. Posttransplantation lymphoproliferative disorders. Pediatr Clin North Am 2003; 50:1471 -1491.
7. Puliyanda DP, Stablein DM, Dharnidharka VR. Younger age and antibody induction increase the risk for infection in pediatric renal transplantation: a NAPRTCS report. Am J Transplant 2007; 7:662-666.
8. Dharnidharka VR, Araya CE. Post-transplant lymphoproliferative disease. Pediatr Nephrol 2007 [Epub ahead of print].
9. McDonald RA, McIntosh M, Stablein DM, et al. Increased incidence of PTLD in pediatric renal transplant recipients enrolled in a randomized controlled trial of steroid withdrawal: a study of the CCTPT. Am J Transplant 2005; 5:418.
10. Smith JM, Dharnidharka VR, Talley L, et al. BK virus nephropathy in pediatric renal transplant recipients: an analysis of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) registry. Clin J Am Soc Nephrol 2007; 2:1037-1042.
11. Smith JM, McDonald RA, Finn LS, et al. Polyomavirus nephropathy in pediatric kidney transplant recipients. Am J Transplant 2004; 4:2109-2117.
12. Dharnidharka VR, Stablein DM, Harmon WE. Posttransplant infections now exceed acute rejection as cause for hospitalization: a report of the NAPRTCS. Am J Transplant 2004; 4:384-389.
13. Dharnidharka VR, Caillard S, Agodoa LY, Abbott KC. Infection frequency and profile in different age groups of kidney transplant recipients. Transplantation 2006; 81:1662-1667.
14. Solez K, Vincenti F, Filo RS. Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tarolimus versus cyclosporine: a report of the FK506 Kidney Transplant Study Group. Transplantation 1998; 66:1736-1740.
15. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349:931-940.
16. Sarwal MM, Yorgin PD, Alexander S, et al. Promising early outcomes with a novel, complete steroid avoidance immunosuppression protocol in pediatric renal transplantation. Transplantation 2001; 72:13-21.
17. Sarwal MM, Vidhun JR, Alexander SR, et al. Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation. Transplantation 2003; 76:1331-1339.
18. Meier-Kriesche HU, Magee JC, Kaplan B. Trials and tribulations of steroid withdrawal after kidney transplantation. Am J Transplant 2008; 8:265-266.
19. Boots JM, Christiaans MH,van Hooff JP. Effect of immunosuppressive agents on long-term survival of renal transplant recipients: focus on the cardiovascular risk. Drugs 2004; 64:2047-2073.
20. Ferraris JR, Ghezzi L, Waisman G, Krmar RT. Potential cardiovascular risk factors in paediatric renal transplant recipients. Pediatr Nephrol 2006; 21:119-125.
21. Becker-Cohen R, Nir A, Rinat C, et al. Risk factors for cardiovascular disease in children and young adults after renal transplantation. Clin J Am Soc Nephrol 2006; 1:1284-1292.
22. Owen RD. Immunogenetic consequences of vascular anastomoses between bovine twins. Science 1945; 102:400-401.
23. Adams AB, Williams MA, Jones TR, et al. Heterologous immunity provides a potent barrier to transplantation tolerance. J Clin Invest 2003; 111:1887-1895.
24. Koyama I, Nadazdin O, Boskovic S, et al. Depletion of CD8 memory T cells for induction of tolerance of a previously transplanted kidney allograft. Am J Transplant 2007; 7:1055-1061.
25. McFarland RD, Douek DC, Koup RA, Picker LJ. Identification of a human recent thymic emigrant phenotype. Proc Natl Acad Sci USA 2000; 97: 4215-4220.
26. Pitcher CJ, Hagen SI, Walker JM, et al. Development and homeostasis of T cell memory in rhesus macaque. J Immunol 2002; 168:29-43.
27. Komatsu H, Inui A, Sogo T, et al. Large scale analysis of pediatric antiviral CD8+ T cell populations reveals sustained, functional and mature responses. Immun Ageing 2006; 3:11.
28. Slavin S, Gottlieb M, Strober S, et al. Transplantation of bone marrow in outbred dogs without graft-versus-host disease using total lymphoid irradiation. Transplantation 1979; 27:139-142.
29. Myburgh JA, Smit JA, Stark JH, Browde S. Total lymphoid irradiation in kidney and liver transplantation in the baboon: prolonged graft survival and alterations in T cell subsets with low cumulative dose regimens. J Immunol 1984; 132:1019-1025.
30. Strober S, Dhillon M, Schubert M, et al. Acquired immune tolerance to cadaveric renal allografts. A study of three patients treated with total lymphoid irradiation. N Engl J Med 1989; 321:28-33.
31. StroberS, Benike C, Krishnaswamy S, et al. Clinical transplantation tolerance twelve years after prospective withdrawal of immunosuppressive drugs: studies of chimerism and antidonor reactivity. Transplantation 2000; 69: 1549-1554.
32. Saper V, Chow D, Engleman ED, et al. Clinical and immunological studies of cadaveric renal transplant recipients given total-lymphoid irradiation and maintained on low-dose prednisone. Transplantation 1988; 45:540-546.
33. Millan MT, Shizuru JA, Hoffmann P, et al. Mixed chimerism and immunosuppressive drug withdrawal after HLA-mismatched kidney and hematopoietic progenitor transplantation. Transplantation 2002; 73:1386-1391.
34. Millan MT SJ, Shizuru J, Lowsky R, Strober S. Studies of tolerance and chimerism after combined blood stem cell and kidney transplantation in humans. Am J Transplant 2005; 5 (Suppl 11):544.
35. Scandling JD, Busque S, Dejbakhsh-Jones S, et al. Tolerance and chimerism after renal and hematopoietic-cell transplantation. N Engl J Med 2008; 358:362-368.
36. Kirk AD, Sollinger HW, Vincenti F, et al. Preliminary results of the use of humanized anti-CD154 in human renal allotransplantation. Am J Transplant 2001; 1:S191.
37. Larsen CP, Pearson TC, Adams AB, et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 2005; 5:443-453.
38. Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005; 353:770-781.
39. Calne R, Friend P, MoffattS, et al. Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet 1998; 351:1701 -1702.
40. Bartosh SM, Knechtle SJ, Sollinger HW. Campath-1H use in pediatric renal transplantation. Am J Transplant 2005; 5:1569-1573.
41. Bartosh SM, Sanchez CP, Sollinger HW, Knechtle SJ. Pilot trial of steroid free immunosuppression with Campath-1H in low risk pediatric kidney transplants. Pediatr Transplant 2007; 11:37.
42. Shapiro R, Ellis D,Tan HP, et al. Alemtuzumab preconditioning with tacrolimus monotherapy in pediatric renal transplantation. Am J Transplant 2007; 7: 2736-2738.
43. Starzl TE, Demetris AJ. Transplantation tolerance, microchimerism, and the two-way paradigm. Theor Med Bioeth 1998; 19:441-455.
44. Monaco AP, Wood ML. Studies on heterologous antilymphocyte serum in mice. VII. Optimal cellular antigen for induction of immunologic tolerance with antilymphocyte serum. Transplant Proc 1970; 2:489-496.
45. Thomas JM, Neville DM, Contreras JL, et al. Preclinical studies of allograft tolerance in rhesus monkeys: a novel anti-CD3-immunotoxin given peritransplant with donor bone marrow induces operational tolerance to kidney allografts. Transplantation 1997; 64:124-135.
46. Starzl TE, MuraseN, Abu-Elmagd K, et al. Tolerogenic immunosuppression for organ transplantation. Lancet 2003; 361:1502-1510.
47. Barber WH, Mankin JA, Laskow DA, et al. Long-term results of a controlled prospective study with transfusion of donor-specific bone marrow in 57 cadaveric renal allograft recipients. Transplantation 1991; 51:70-75.
48. Ciancio G, Burke GW, Garcia-Morales R, et al. Effect of living-related donor bone marrow infusion on chimerism and in vitro immunoregulatory activity in kidney transplant recipients. Transplantation 2002; 74:488-496.
49. Tryphonopoulos P, Tzakis AG, Weppler D, et al. The role of donor bone marrow infusions in withdrawal of immunosuppression in adult liver allotransplantation. Am J Transplant 2005; 5:608-613.
50. Light J, Salomon DR, Diethelm AG, et al. Bone marrow transfusions in cadaver renal allografts: pilot trials with concurrent controls. Clin Transplant 2002; 16:317-324.
51. Delis S, Burke GW 3rd, Ciancio G. Bone marrow-induced tolerance in the era of pancreas and islets transplantation. Pancreas 2006; 32:1-8.
52. Sharabi Y, Sachs DH. Engraftment of allogeneic bone marrow following administration of anti-T cell monoclonal antibodies and low-dose irradiation. Transplant Proc 1989; 21:233-235.
53. Kawai T, Cosimi AB, Colvin RB, et al. Mixed allogeneic chimerism and renal allograft tolerance in cynomolgus monkeys. Transplantation 1995; 59:256-262.
54. Buhler LH, Spitzer TR, Sykes M, et al. Inductionof kidney allograft tolerance after transient lymphohematopoietic chimerism inpatients with multiple myeloma and end-stage renal disease. Transplantation 2002; 74:1405-1409.
55. Fudaba Y, Spitzer TR, Shaffer J, et al. Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: in vivo and in vitro analyses. Am J Transplant 2006; 6:2121-2133.
56. SpitzerTR, Delmonico F, Tolkoff-Rubin N, et al. Combined histocompatibility leukocyte antigen-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: the induction of allograft tolerance through mixed lymphohematopoietic chimerism. Transplantation 1999; 68:480-484.
57. Kawai T, Cosimi AB, Spitzer TR, et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med 2008; 358:353-361.
58. Bullington P, Pawola L, Walker R, et al. Identification of medication nonadherence factors in adolescent transplant patients: the patient's viewpoint. Pediatr Transplant 2007; 11:914-921.
59. Gremigni P, Bacchi F, Turrini C, et al. Psychological factors associated with medication adherence following renal transplantation. Clin Transplant 2007; 21:710-715.
60. Smith JM, Ho PL, McDonald RA. Renal transplant outcomes in adolescents: a report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Transplant 2002; 6:493-499.
61. KyngAs HA, Kroll T, Duffy ME. Compliance in adolescents with chronic diseases: a review. J Adolesc Health 2000; 26:379-388.